0001595097falseNONE00015950972024-06-142024-06-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2024

 

 

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

500 River Ridge Drive

 

Norwood, Massachusetts

 

02062

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

CRBP

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On June 14, 2024, Yong Ben M.D., a member of the board of directors of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), adopted a Rule 10b5-1 plan providing for the sale of up to 10,607 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Pursuant to this plan, Dr. Ben may sell shares of Common Stock beginning on September 12, 2024, subject to the terms of the agreement, and the plan terminates on September 11, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

June 17, 2024

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer

 

v3.24.1.1.u2
Document And Entity Information
Jun. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 14, 2024
Entity Registrant Name CORBUS PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key 0001595097
Entity Emerging Growth Company false
Entity File Number 001-37348
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-4348039
Entity Address, Address Line One 500 River Ridge Drive
Entity Address, City or Town Norwood
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02062
City Area Code (617)
Local Phone Number 963-0100
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CRBP
Security Exchange Name NONE
Corbus Pharmaceuticals (NASDAQ:CRBP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Corbus Pharmaceuticals.
Corbus Pharmaceuticals (NASDAQ:CRBP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Corbus Pharmaceuticals.